Research programme: adenosine 1 receptor agonists - Bayer
Latest Information Update: 23 Mar 2010
At a glance
- Originator Bayer
- Mechanism of Action Adenosine A1 receptor agonists; Purinergic P1 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Acute coronary syndromes; Angina pectoris; Atrial fibrillation; Metabolic syndrome